NOI to Sole Source to QuVa Pharma, Inc.
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH) intends to award a firm fixed-price sole source contract to QuVa Pharma, Inc. for the purchase of 503b compounded Intravenous (IV) Narcotics for patient care at the NIH Clinical Center in Bethesda, MD. This is a Notice of Intent, not a request for quotation. Comments are due by May 6, 2026, at 9 am EST.
Scope of Work
This acquisition is for 503b compounded Intravenous (IV) Narcotics required for patient care at the NIH Clinical Center, a research hospital. These medications are essential for patients participating in clinical trials. The requirement falls under Product Service Code 6515 (Medical And Surgical Instruments, Equipment, And Supplies) and NAICS Code 325412 (Pharmaceutical Preparation Manufacturing).
Contract Details
- Type: Firm Fixed-Price, Sole Source (Notice of Intent)
- Proposed Contractor: QuVa Pharma, Inc. (Sugarland, TX)
- Estimated Value: A Blanket Purchase Agreement (BPA) with a base year valued at $110,000 and four optional years, totaling an estimated $684,000.
- Duration: One base year plus four option years.
- Set-Aside: None (sole source action).
- Place of Performance: NIH Clinical Center, Bethesda, MD 20892 USA.
- Authority: This acquisition is conducted under FAR Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), which allows for sole source awards when only one source is reasonably available. It is also justified under 41 U.S.C. 3304(a)(1) (FAR 6.302-1 – Only One Responsible Source).
Justification for Sole Source
Market research identified QuVa Pharma, Inc. as the Original Manufacturer of these IV narcotics, with no other designated distributors in the U.S. While other FDA-registered pharmacies can compound this medication, it is not readily available through normal prime vendor distribution channels. The NIH Clinical Center Pharmacy Department continuously monitors the industry for availability.
Response Information
This is a notice of intent, and a solicitation document will not be issued. The Government's determination not to compete this requirement is solely at its discretion. Interested parties may submit comments referencing the posting number to Huda Malik, Contract Specialist, via email at huda.malik@nih.gov by May 6, 2026, at 9 am EST.